{"id":44754,"date":"2022-06-06T17:01:18","date_gmt":"2022-06-06T15:01:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/"},"modified":"2022-06-06T17:01:18","modified_gmt":"2022-06-06T15:01:18","slug":"serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/","title":{"rendered":"Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains"},"content":{"rendered":"<div>\n<p>\n<i>The collaboration will utilize the Serotiny platform to design, analyze, evaluate, and screen Multi-Domain Protein libraries aiming to identify novel Chimeric Antigen Receptors (CAR) signaling domains<\/i>\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220606005160\/en\/1476345\/5\/Fire.1024-name_%285%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220606005160\/en\/1476345\/21\/Fire.1024-name_%285%29.jpg\"><\/a><\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to optimize CAR designs for cellular therapy. The collaboration will leverage Serotiny\u2019s tMDP mining and design capabilities with Janssen\u2019s antibody development and cell therapy expertise to create next generation CAR-based cell therapies that will potentially have improved therapeutic function and enhanced clinical benefit. The agreement was facilitated by Johnson &amp; Johnson Innovation.\n<\/p>\n<p>\n\u201c<!-- no quote -->We\u2019re excited to be working with Janssen scientists,\u201d said Colin Farlow, J.D., Serotiny\u2019s CEO. \u201c<!-- no quote -->At Serotiny, we look forward to advancing our platform and efforts in discovering and developing proteins with novel function for the purpose of enhancing the therapeutic utility of next-generation cell therapies.\u201d\n<\/p>\n<p>\nSerotiny is located at the Johnson &amp; Johnson Innovation \u2013 JLABS incubator in South San Francisco, CA.\n<\/p>\n<p>\n<b>About Serotiny<\/b>\n<\/p>\n<p>\nSerotiny is a pre-clinical discovery company building better gene and cell therapies through engineering Therapeutic Multi-Domain Proteins (tMDP) such as Chimeric Antigen Receptors (CARs), alternative CARs, accessory proteins and gene editing systems in high-throughput. At the heart of Serotiny\u2019s technology is a discovery platform that harmonizes computationally aided protein design, high-throughput cellular assays, and next generation sequencing, in order to engineer multi-domain proteins. Serotiny\u2019s platform utilizes proprietary constraints to engineer large and often unstructured multi-domain proteins to control the properties of the mammalian cells in which they are expressed. Serotiny encodes these constraints into its platform to create a scaled design-build-test-learn process that takes advantage of a cross disciplinary approach utilizing synthetic biology, immunology, machine learning, software engineering and bioinformatics. For more info visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.serotiny.bio&amp;esheet=52739212&amp;newsitemid=20220606005160&amp;lan=en-US&amp;anchor=www.serotiny.bio&amp;index=1&amp;md5=b2348072203ff7c83db50d3744c234d8\" rel=\"nofollow noopener\" shape=\"rect\">www.serotiny.bio<\/a>, or contact Colin Farlow at <a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#x6f;&#x3a;&#x69;&#x6e;fo&#64;&#115;&#101;&#x72;&#x6f;&#x74;&#x69;ny&#46;&#98;&#105;&#x6f;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x6e;&#x66;&#x6f;&#64;&#115;&#101;ro&#x74;&#x69;&#x6e;&#x79;&#x2e;&#98;&#105;&#111;<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nColin Farlow, <a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#x6f;:&#105;&#x6e;&#102;&#x6f;&#64;&#x73;e&#114;&#x6f;&#116;&#x69;n&#x79;&#46;&#98;&#x69;&#111;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x6e;&#x66;&#x6f;&#x40;&#x73;&#x65;&#114;&#111;&#116;&#105;&#110;y&#46;bi&#x6f;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The collaboration will utilize the Serotiny platform to design, analyze, evaluate, and screen Multi-Domain Protein libraries aiming to identify novel Chimeric Antigen Receptors (CAR) signaling domains SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44754","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The collaboration will utilize the Serotiny platform to design, analyze, evaluate, and screen Multi-Domain Protein libraries aiming to identify novel Chimeric Antigen Receptors (CAR) signaling domains SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-06T15:01:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220606005160\/en\/1476345\/21\/Fire.1024-name_%285%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains\",\"datePublished\":\"2022-06-06T15:01:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/\"},\"wordCount\":340,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220606005160\\\/en\\\/1476345\\\/21\\\/Fire.1024-name_%285%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/\",\"name\":\"Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220606005160\\\/en\\\/1476345\\\/21\\\/Fire.1024-name_%285%29.jpg\",\"datePublished\":\"2022-06-06T15:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220606005160\\\/en\\\/1476345\\\/21\\\/Fire.1024-name_%285%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220606005160\\\/en\\\/1476345\\\/21\\\/Fire.1024-name_%285%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/","og_locale":"en_US","og_type":"article","og_title":"Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains - Pharma Trend","og_description":"The collaboration will utilize the Serotiny platform to design, analyze, evaluate, and screen Multi-Domain Protein libraries aiming to identify novel Chimeric Antigen Receptors (CAR) signaling domains SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-06T15:01:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220606005160\/en\/1476345\/21\/Fire.1024-name_%285%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains","datePublished":"2022-06-06T15:01:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/"},"wordCount":340,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220606005160\/en\/1476345\/21\/Fire.1024-name_%285%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/","url":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/","name":"Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220606005160\/en\/1476345\/21\/Fire.1024-name_%285%29.jpg","datePublished":"2022-06-06T15:01:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220606005160\/en\/1476345\/21\/Fire.1024-name_%285%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220606005160\/en\/1476345\/21\/Fire.1024-name_%285%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/serotiny-announces-a-research-collaboration-with-janssen-to-optimize-designs-for-chimeric-antigen-receptors-signaling-domains\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44754"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44754\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}